Numerous landmark clinical trials in people with T2DM have now confirmed the irrefutable benefits of SGLT2 inhibitors for reducing mortality and CV risk as well as preventing both incident or recurrent hospitalisation for heart failure (HHF) and declining renal function [13–21]. Here, SLC5A2 is linked to heart failure.